A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone MetastasesRichard J. Lee, Matthew R. Smith, Jonathan Goldin et al.|Clinical Cancer Research|2013Cited by 74
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate CancerPhilip J. Saylor, David T. Miyamoto, Keisuke Otani et al.|JCO Precision Oncology|2024Cited by 7
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.Richard J. Lee, Matthew R. Smith, M. Dror Michaelson et al.|Journal of Clinical Oncology|2012Cited by 2
Integrated Gene Expression Score in Circulating Tumor Cells to Predict Treatment Response in Muscle-Invasive Bladder CancerWilliam L. Hwang, David T. Miyamoto, Haley M. Pleskow et al.|International Journal of Radiation Oncology*Biology*Physics|2019Cited by 2
Circulating Tumor Cells and Radium-223 Response in Metastatic Castration-Resistant Prostate CancerHaley M. Pleskow, D.T. Miyamoto, Keiko Otani et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 2